What Krystexxa treats.
- Chronic gout refractory to conventional therapy
- Tophaceous gout (visible uric acid deposits)
The mechanism.
Krystexxa (pegloticase) is an enzyme that converts uric acid into allantoin, a compound the body can readily excrete. For patients whose gout doesn’t respond to standard medications like allopurinol or febuxostat, Krystexxa rapidly lowers uric acid and dissolves stubborn deposits.
Your Krystexxa infusion experience.
Krystexxa infusions take about 2 hours and are given every 2 weeks. Pre-medications (antihistamines and steroids) are required to reduce infusion reactions. Your physician will check uric acid levels before each infusion — rising levels may indicate that treatment should stop.
Insurance & out-of-pocket cost.
Krystexxa is covered by most commercial insurance and Medicare Part B when prescribed by your physician for an FDA-approved indication. We verify your benefits before your first infusion and handle prior authorization on your behalf. Most commercially insured patients pay only their standard specialty copay — typically $20–$100 per visit. Manufacturer copay assistance programs may further reduce your cost.